MyMyelomaTeam

Teclistamab (brand name Tecvayli) is a newer treatment option that has shown promising results for people with relapsed myeloma. Clinical studies have demonstrated that about 62% of patients responded to teclistamab treatment, with two-thirds of those patients maintaining their response at least 9 months after starting Show Full Answer

Teclistamab (brand name Tecvayli) is a newer treatment option that has shown promising results for people with relapsed myeloma. Clinical studies have demonstrated that about 62% of patients responded to teclistamab treatment, with two-thirds of those patients maintaining their response at least 9 months after starting treatment. While Darzalex works by targeting CD38 on myeloma cells, teclistamab uses a different approach as a bispecific T-cell engager (BiTE). The FDA has approved it specifically for treating relapsed or refractory multiple myeloma. Studies suggest it may help improve both progression-free survival and overall survival compared to standard treatments. It's important to discuss this treatment option with your healthcare team, as they can evaluate if teclistamab might be appropriate for your specific situation based on your treatment history and current health status.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Bispecific T-Cell Engagers for RRMM: 6 Facts About a New Type of Treatment

Multiple Myeloma Maintenance Therapy: 6 Facts